GlobeNewswire·Aug 12, 2026, 4:01 PM ET

Journey Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Total revenues for the second quarter of 2026 reached $18.5 million, representing a 23% increase from the prior-year quarter.
Emrosi® revenues totaled $8.1 million for the second quarter of 2026, driving the overall growth.
Gross margin remained consistent at 67% for the second quarter of 2026 compared to the prior-year period.
Selling, general, & administrative expenses decreased by $1.0 million to $10.9 million, primarily due to reduced launch-related spending for Emrosi®.
GAAP Net Loss narrowed to $0.3 million ($0.01 per share) for the second quarter of 2026, compared to a loss of $3.8 million ($0.16 per share) in the prior-year quarter.
Non-GAAP Adjusted EBITDA was positive at $2.862 million for the three-month period ended June 30, 2026, compared to a negative $476,000 in the prior year.
The Company held $25.6 million in cash & cash equivalents as of June 30, 2026, up from $24.1 million at December 31, 2025.
Total prescriptions (TRx) for Emrosi® were approximately 36,000 in the second quarter of 2026, increasing from 30,000 in the first quarter & 27,000 in the fourth quarter of 2025.
Journey Medical announced a conference call for August 12, 2026, at 4:30 p.m. ET to discuss financial results.
The Company markets nine branded FDA-approved prescription drugs for dermatological conditions & is headquartered in Scottsdale, Arizona.